Analysts Discuss the Evolving CytomX Narrative Following Recent Clinical Progress and Increased Price Target
Analyst Price Target Increase: CytomX Therapeutics' consensus analyst price target has risen from $6.14 to $7.07 per share, driven by positive clinical developments for its lead asset, CX-2051, in the colorectal cancer market.
Positive Analyst Sentiment: Analysts from firms like Oppenheimer and Cantor Fitzgerald have expressed bullish views on CytomX, highlighting the potential of CX-2051 and its strategic positioning, while Barclays remains more cautious with a lower price target.
Financial Stability and Future Projections: The company is noted for its strengthened financial position, with a cash runway expected to support operations through key clinical milestones in 2026, despite some concerns about the complexity of the colorectal cancer market.
Upcoming Data Presentation: CytomX is set to present initial data from its Phase 1 study of CX-801 for advanced melanoma at an upcoming conference, which could provide further insights into its early-stage pipeline and scientific approach.
Trade with 70% Backtested Accuracy
Analyst Views on CTMX
About CTMX
About the author
Birkenstock, Insmed, and Other Major Stocks Decline in Thursday's Pre-Market Trading
U.S. Stock Futures: U.S. stock futures rose this morning, with Dow futures increasing by approximately 100 points.
Birkenstock Earnings Report: Birkenstock Holding PLC's shares fell 10.6% in pre-market trading despite reporting quarterly earnings of 60 cents per share, surpassing analyst expectations.
Other Stocks Declining: Several stocks, including Insmed Inc and DBV Technologies, experienced significant declines in pre-market trading due to various company announcements and performance issues.
Instacart Investigation: Instacart's shares dropped 6.6% amid reports of a U.S. Federal Trade Commission investigation into its AI pricing tool.
Analysts Discuss the Evolving CytomX Narrative Following Recent Clinical Progress and Increased Price Target
Analyst Price Target Increase: CytomX Therapeutics' consensus analyst price target has risen from $6.14 to $7.07 per share, driven by positive clinical developments for its lead asset, CX-2051, in the colorectal cancer market.
Positive Analyst Sentiment: Analysts from firms like Oppenheimer and Cantor Fitzgerald have expressed bullish views on CytomX, highlighting the potential of CX-2051 and its strategic positioning, while Barclays remains more cautious with a lower price target.
Financial Stability and Future Projections: The company is noted for its strengthened financial position, with a cash runway expected to support operations through key clinical milestones in 2026, despite some concerns about the complexity of the colorectal cancer market.
Upcoming Data Presentation: CytomX is set to present initial data from its Phase 1 study of CX-801 for advanced melanoma at an upcoming conference, which could provide further insights into its early-stage pipeline and scientific approach.
HC Wainwright & Co. Reaffirms Buy Rating for CytomX Therapeutics and Increases Price Target to $10
- Real-time Intelligence: Benzinga Pro offers the fastest news alerts for traders to stay updated on market movements.
- Exclusive Content: The platform provides exclusive stories and insights generated by Benzinga reporters for its users.
- Community Engagement: Over 10,000 serious traders are part of the Benzinga Pro community, enhancing their trading strategies.
- Market Winning Tools: The service is designed to help traders win in the markets every day with accurate stock market intelligence.
CytomX announces Q1 2026 data update for CX-2051 and achieves 100-patient enrollment milestone as Phase Ib study progresses.
Management Updates: CytomX Therapeutics appointed Rachael Lester as Chief Business Officer to enhance strategic planning and business development, while CEO Sean McCarthy highlighted the promising interim Phase I data for CX-2051, targeting colorectal cancer with a potential new standard of care.
Clinical Development Plans: The company plans to expand the Phase I study of CX-2051 to about 100 patients by Q1 2026 and initiate a Phase Ib study with bevacizumab, alongside updates on additional indications for CX-2051 and CX-801-KEYTRUDA combination data expected in 2026.
Financial Performance: CytomX reported a significant revenue drop to $6 million in Q3 2025, down from $33.4 million in the previous year, primarily due to completed collaboration obligations, while maintaining a cash balance sufficient to fund operations through at least Q2 2027.
Analyst Sentiment and Risks: Analysts expressed optimism regarding the progress of CX-2051 and the company's pipeline, although concerns were raised about managing gastrointestinal adverse events and the need for a clear regulatory strategy as the dataset matures.
CytomX Therapeutics Stock: An In-Depth Look at Analyst Opinions (4 Ratings)
Analyst Ratings Overview: Recent evaluations of CytomX Therapeutics show a mix of bullish and bearish sentiments, with 4 analysts providing ratings that include 1 somewhat bullish rating in the last 30 days, while the average price target has increased to $5.62 from $3.50.
Company Profile: CytomX Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative cancer therapies using its probody technology, which aims to enhance tumor targeting while minimizing effects on healthy tissues.
Financial Performance: The company has faced challenges with a negative revenue trend, reporting a decline of approximately 25.71% in revenue growth over the past three months, although it maintains a strong net margin and return on equity compared to industry averages.
Analyst Insights: Analysts provide ongoing assessments and predictions for CytomX Therapeutics, reflecting their expectations based on market conditions and company performance, which can guide investors in making informed decisions.
Barclays Keeps Overweight Rating on CytomX Therapeutics and Increases Price Target to $6
Real-time Intelligence: Benzinga Pro offers the fastest news alerts for traders, providing real-time market intelligence to help them succeed.
Exclusive Stories: The platform features exclusive stories generated by Benzinga reporters, enhancing the trading experience for its users.
Community of Traders: Over 10,000 serious traders are part of the Benzinga Pro community, sharing insights and strategies.
Market Winning Tools: Benzinga Pro equips traders with tools and information necessary to make informed decisions and win in the markets daily.
Birkenstock, Insmed, and Other Major Stocks Decline in Thursday's Pre-Market Trading
U.S. Stock Futures: U.S. stock futures rose this morning, with Dow futures increasing by approximately 100 points.
Birkenstock Earnings Report: Birkenstock Holding PLC's shares fell 10.6% in pre-market trading despite reporting quarterly earnings of 60 cents per share, surpassing analyst expectations.
Other Stocks Declining: Several stocks, including Insmed Inc and DBV Technologies, experienced significant declines in pre-market trading due to various company announcements and performance issues.
Instacart Investigation: Instacart's shares dropped 6.6% amid reports of a U.S. Federal Trade Commission investigation into its AI pricing tool.
Analysts Discuss the Evolving CytomX Narrative Following Recent Clinical Progress and Increased Price Target
Analyst Price Target Increase: CytomX Therapeutics' consensus analyst price target has risen from $6.14 to $7.07 per share, driven by positive clinical developments for its lead asset, CX-2051, in the colorectal cancer market.
Positive Analyst Sentiment: Analysts from firms like Oppenheimer and Cantor Fitzgerald have expressed bullish views on CytomX, highlighting the potential of CX-2051 and its strategic positioning, while Barclays remains more cautious with a lower price target.
Financial Stability and Future Projections: The company is noted for its strengthened financial position, with a cash runway expected to support operations through key clinical milestones in 2026, despite some concerns about the complexity of the colorectal cancer market.
Upcoming Data Presentation: CytomX is set to present initial data from its Phase 1 study of CX-801 for advanced melanoma at an upcoming conference, which could provide further insights into its early-stage pipeline and scientific approach.
HC Wainwright & Co. Reaffirms Buy Rating for CytomX Therapeutics and Increases Price Target to $10
- Real-time Intelligence: Benzinga Pro offers the fastest news alerts for traders to stay updated on market movements.
- Exclusive Content: The platform provides exclusive stories and insights generated by Benzinga reporters for its users.
- Community Engagement: Over 10,000 serious traders are part of the Benzinga Pro community, enhancing their trading strategies.
- Market Winning Tools: The service is designed to help traders win in the markets every day with accurate stock market intelligence.
CytomX announces Q1 2026 data update for CX-2051 and achieves 100-patient enrollment milestone as Phase Ib study progresses.
Management Updates: CytomX Therapeutics appointed Rachael Lester as Chief Business Officer to enhance strategic planning and business development, while CEO Sean McCarthy highlighted the promising interim Phase I data for CX-2051, targeting colorectal cancer with a potential new standard of care.
Clinical Development Plans: The company plans to expand the Phase I study of CX-2051 to about 100 patients by Q1 2026 and initiate a Phase Ib study with bevacizumab, alongside updates on additional indications for CX-2051 and CX-801-KEYTRUDA combination data expected in 2026.
Financial Performance: CytomX reported a significant revenue drop to $6 million in Q3 2025, down from $33.4 million in the previous year, primarily due to completed collaboration obligations, while maintaining a cash balance sufficient to fund operations through at least Q2 2027.
Analyst Sentiment and Risks: Analysts expressed optimism regarding the progress of CX-2051 and the company's pipeline, although concerns were raised about managing gastrointestinal adverse events and the need for a clear regulatory strategy as the dataset matures.
CytomX Therapeutics Stock: An In-Depth Look at Analyst Opinions (4 Ratings)
Analyst Ratings Overview: Recent evaluations of CytomX Therapeutics show a mix of bullish and bearish sentiments, with 4 analysts providing ratings that include 1 somewhat bullish rating in the last 30 days, while the average price target has increased to $5.62 from $3.50.
Company Profile: CytomX Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative cancer therapies using its probody technology, which aims to enhance tumor targeting while minimizing effects on healthy tissues.
Financial Performance: The company has faced challenges with a negative revenue trend, reporting a decline of approximately 25.71% in revenue growth over the past three months, although it maintains a strong net margin and return on equity compared to industry averages.
Analyst Insights: Analysts provide ongoing assessments and predictions for CytomX Therapeutics, reflecting their expectations based on market conditions and company performance, which can guide investors in making informed decisions.
Barclays Keeps Overweight Rating on CytomX Therapeutics and Increases Price Target to $6
Real-time Intelligence: Benzinga Pro offers the fastest news alerts for traders, providing real-time market intelligence to help them succeed.
Exclusive Stories: The platform features exclusive stories generated by Benzinga reporters, enhancing the trading experience for its users.
Community of Traders: Over 10,000 serious traders are part of the Benzinga Pro community, sharing insights and strategies.
Market Winning Tools: Benzinga Pro equips traders with tools and information necessary to make informed decisions and win in the markets daily.
